Sysmex Inostics GmbH
26.01.2022 - 16:00
Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated ...
To the press release of Sysmex Inostics GmbH20.10.2021 - 16:30
Baltimore, MD (ots) - -- New Tool for Detection of Minimal Residual Disease in Acute Myeloid Leukemia to Better Help in Fight Against Cancer -- Sysmex Inostics has developed a new CLIA-validated liquid biopsy test for the detection of Minimal ...
To the press release of Sysmex Inostics GmbH02.06.2021 - 15:00
Baltimore, MD (ots) - Sysmex Inostics presents data at ASCO showing HPV-SEQ, a new CLIA-validated SafeSEQ NGS HPV16/18 liquid biopsy assay, is highly effective for measuring HPV DNA in the plasma of patients with oropharyngeal squamous cell ...
To the press release of Sysmex Inostics GmbH10.04.2021 - 14:30
Baltimore, MD, USA (ots) - Sysmex Inostics, Inc., a global leader of the liquid biopsy revolution for oncology, is presenting the poster “Clinical evaluation of NGS-based liquid biopsy testing in non-small cell lung cancer (NSCLC) patients” at ...
To the press release of Sysmex Inostics GmbH05.12.2020 - 16:00
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based, high-sensitivity molecular testing for oncology, is presenting the poster "Ultrasensitive Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia ...
To the press release of Sysmex Inostics GmbH08.09.2020 - 12:00
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating cell-free tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study investigating the utility of cfDNA-based ...
To the press release of Sysmex Inostics GmbH27.08.2020 - 12:00
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating RAS mutation status in circulating tumor DNA ...
To the press release of Sysmex Inostics GmbH05.08.2020 - 12:18
Baltimore, Maryland (ots) - Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation ...
To the press release of Sysmex Inostics GmbH10.03.2020 - 12:00
Baltimore, Maryland (ots) - Building on the ultra-high sensitivity SafeSEQ Breast Cancer Panel circulating tumor DNA (ctDNA) test launched at the American Association of Cancer Research 2019 annual meeting, Sysmex Inostics has updated the test to ...
To the press release of Sysmex Inostics GmbH28.01.2020 - 12:00
Hamburg, Germany and Baltimore, Maryland (ots) - Pathologist Dr. Vincente Peg of the Vall d´Hebron University Hospital (Barcelona Spain) and colleagues have presented a correlation between the clearance of circulating tumor DNA (ctDNA) in ...
To the press release of Sysmex Inostics GmbH16.12.2019 - 12:00
Hamburg, Germany and Baltimore, Maryland (ots) - New data presented by Dr. Ben Ho Park, Professor of Medicine and Director of Precision Oncology at Vanderbilt University and colleagues at the recent San Antonio Breast Cancer Symposium (SABCS) in San ...
To the press release of Sysmex Inostics GmbH27.09.2019 - 12:00
Hamburg, Germany and Baltimore, Maryland (ots) - Sysmex Inostics announces the availability of the SafeSEQ Breast Cancer and Head and Neck Cancer Panels along with the SafeSEQ Rapid Custom Development program for circulating tumor DNA (ctDNA) ...
To the press release of Sysmex Inostics GmbH04.09.2019 - 12:00
Hamburg/Baltimore (ots) - Using Sysmex Inostics' novel SafeSEQ next-generation sequencing cell-free DNA technology, investigators from the Biomedical Research Institute of Malaga [(IBIMA)-CIMES-UMA, Malaga Spain] and collaborators have published the ...
To the press release of Sysmex Inostics GmbH02.08.2019 - 08:00
Kobe, Japan (ots) - Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBEAM(TM) RAS CRC Kit, used for blood-based circulating tumor DNA (ctDNA) molecular testing of mutations in the RAS gene for advanced ...
To the press release of Sysmex Inostics GmbH18.07.2019 - 12:00
Hamburg, Germany (ots) - Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces publication of a study comparing the performance of plasma RAS mutation detection ...
To the press release of Sysmex Inostics GmbH30.05.2019 - 12:00
Hamburg/Baltimore (ots) - Sysmex Inostics announces the publication of clinical research conducted as part of the CIRculating CANcer (CIRCAN) Program at the Lyon Cancer Institute (Lyon, France) comparing the performance of Sysmex Inostics BEAMing ...
To the press release of Sysmex Inostics GmbH28.05.2019 - 12:00
Hamburg/Baltimore (ots) - Recent data presented by Dr. Hope S. Rugo from the University of California San Francisco on behalf of investigators in the Translational Breast Cancer Research Consortium at the American Association of Cancer Research 2019 ...
To the press release of Sysmex Inostics GmbH25.02.2019 - 12:00
Hamburg, Germany (ots) - Data recently published in Clinical Cancer Research (http://ots.de/0ZGZkf) the advantages of using an ultra-high sensitivity test for detection of mutations which may predict therapeutic efficacy for hepatocellular carcinoma ...
To the press release of Sysmex Inostics GmbH05.11.2018 - 12:00
Hamburg, Germany (ots) - Recent data published in Annals of Oncology (https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy417/5139593) from a study conducted by Sysmex Inostics and University of Munich indicate that circulating ...
To the press release of Sysmex Inostics GmbH18.10.2018 - 12:00
Hamburg, Germany (ots) - Data presented at the European Society of Medical Oncology (ESMO) 2018 meeting in Munich, Germany by three clinical oncology research groups demonstrate the importance of a highly sensitive test for detection of ...
To the press release of Sysmex Inostics GmbH15.10.2018 - 13:06
Hamburg, Germany (ots) - Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the ...
To the press release of Sysmex Inostics GmbH 
